RS Cells : Biomarker Summary
Image Description
Here's a summary of immunophenotype of Reed-Sternberg (RS) Cells:
POSITIVE MARKERS: CD30 (>90%), CD15 (75%-85%), PAX5, IRF4/MUM1, intermediate filaments (fascin, restin, vimentin), CD25, HLA-DR (Ia), CD40, CD20 (20%-40%, weak, heterogenous), LMP-1 (20%-75%; depends upon histologic subtype; see table above).
NEGATIVE MARKERS: CD45, CD43, EMA, Cytokeratin, ALK1, CD79a (may be rarely positive), J chain, T-cell markers (mostly negative), BOB1, Oct2 +/-, cytotoxic markers (granzyme B, TIA-1, perforin) +/-
The reactive background lymphocytes in classic Hodgkin lymphomas (cHL) are mostly mature T-cells. The only exception being nodular pattern of lymphocyte-rich cHL which shows predominantly B-cell follicles with expanded mantle zones.
Abbreviations: NSHL nodular sclerosis Hodgkin lymphoma; MCHL mixed cellularity Hodgkin lymphoma; LDHL lymphocyte-depleted Hodgkin lymphoma; LRHL lymphocyte-rich Hodgkin lymphoma; NLPHL nodular lymphocyte predominant Hodgkin lymphoma.
Sources:
Jaffe, E. S. et al (2017). Hematopathology - Second Edition. Philadelphia, PA. Elsevier
Connors, J. M. et al. Hodgkin Lymphoma. Nature Reviews : Disease Primers (2020) 6:61.
POSITIVE MARKERS: CD30 (>90%), CD15 (75%-85%), PAX5, IRF4/MUM1, intermediate filaments (fascin, restin, vimentin), CD25, HLA-DR (Ia), CD40, CD20 (20%-40%, weak, heterogenous), LMP-1 (20%-75%; depends upon histologic subtype; see table above).
NEGATIVE MARKERS: CD45, CD43, EMA, Cytokeratin, ALK1, CD79a (may be rarely positive), J chain, T-cell markers (mostly negative), BOB1, Oct2 +/-, cytotoxic markers (granzyme B, TIA-1, perforin) +/-
The reactive background lymphocytes in classic Hodgkin lymphomas (cHL) are mostly mature T-cells. The only exception being nodular pattern of lymphocyte-rich cHL which shows predominantly B-cell follicles with expanded mantle zones.
Abbreviations: NSHL nodular sclerosis Hodgkin lymphoma; MCHL mixed cellularity Hodgkin lymphoma; LDHL lymphocyte-depleted Hodgkin lymphoma; LRHL lymphocyte-rich Hodgkin lymphoma; NLPHL nodular lymphocyte predominant Hodgkin lymphoma.
Sources:
Jaffe, E. S. et al (2017). Hematopathology - Second Edition. Philadelphia, PA. Elsevier
Connors, J. M. et al. Hodgkin Lymphoma. Nature Reviews : Disease Primers (2020) 6:61.